Literature DB >> 6753908

Long-term captopril treatment in moderate to severe hypertension.

A Santucci, F Aguglia, G De Mattia, C Ficara, F Balsano.   

Abstract

1 The long-term effects of the oral angiotensin-converting enzyme inhibitor captopril with the addition of a diuretic (chlorthalidone) were examined in 16 patients with moderate or grave hypertension. Of these, 14 had essential hypertension and two renovascular hypertension. 2 Blood pressure fell sharply in all patients and this antihypertensive effect was maintained during 2, 4, 6, 12, and 24-month follow-up periods. The efficacy of treatment was not predicted by basal values of plasma renin activity. 3 Urinary excretion of sodium and potassium increased, but the increases were never such as to modify significantly sodium and potassium serum concentration. 4 The long-term treatment was generally well tolerated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753908      PMCID: PMC1427533          DOI: 10.1111/j.1365-2125.1982.tb02061.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients.

Authors:  H R Brunner; H Gavras; B Waeber; G R Kershaw; G A Turini; R A Vukovich; D N McKinstry; I Gavras
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

2.  Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor.

Authors:  H R Brunner; H Gavras; G A Turini; B Waeber; P Cappuis; D N McKinstry
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Radioimmunoassay for aldosterone without chromatography. 2. Determination of plasma aldosterone.

Authors:  W Vetter; H Vetter; W Siegenthaler
Journal:  Acta Endocrinol (Copenh)       Date:  1973-11

5.  Captopril associated granulocytopenia in hypertension after renal transplantation.

Authors:  F Elijovisch; L R Krakoff
Journal:  Lancet       Date:  1980-04-26       Impact factor: 79.321

6.  Captopril and agranulocytosis.

Authors:  J Staessen; R Fagard; P Lijnen; A Amery
Journal:  Lancet       Date:  1980-04-26       Impact factor: 79.321

7.  Immune-complex glomerulopathy in patients treated with captopril.

Authors:  S J Hoorntje; C G Kallenberg; J J Weening; A J Donker; T H The; P J Hoedemaeker
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

8.  Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.

Authors:  B C Campbell; A N Shepherd; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

  8 in total
  3 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

2.  Effective dose range of enalapril in mild to moderate essential hypertension.

Authors:  R Bergstrand; H Herlitz; S Johansson; G Berglund; A Vedin; C Wilhelmsson; H J Gomez; V J Cirillo; J A Bolognese
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

3.  Captopril for refractory hypertension in patients with impaired renal function.

Authors:  M S Laher; P O'Regan; J F O'Donohoe; T B Counihan
Journal:  J R Soc Med       Date:  1985-05       Impact factor: 5.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.